SCHEMBL4862946

SCHEMBL4862946

CN(c1ccco1)c1nc(S(C)(=O)=O)nc2occ(-c3ccccc3)c12

nearest known ligand 0.32

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BPTF Q12830 1/20 0.32
HPGD P15428 3/20 0.32
NPSR1 Q6W5P4 3/20 0.32
RAB9A P51151 3/20 0.32
KDM4E B2RXH2 3/20 0.32
PTGS2 P35354 3/20 0.32
TP53 P04637 2/20 0.32
STAT3 P40763 2/20 0.32
HTT P42858 2/20 0.32
HSD17B10 Q99714 2/20 0.32
ALDH1A1 P00352 2/20 0.32
MAPT P10636 2/20 0.32
TLR9 Q9NR96 2/20 0.32
NPC1 O15118 2/20 0.32
KMT2A Q03164 2/20 0.32
JAK2 O60674 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
TLR8 Q9NR97 1/20 0.32
MEN1 O00255 1/20 0.32
S1PR4 O95977 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4868742 0.76 NPSR1 (0.43) BPTFHPGDNPSR1RAB9AKDM4E
SCHEMBL4862943 0.72 HPGD (0.47) HPGDNPSR1KDM4EPTGS2TP53
SCHEMBL4865898 0.70 PTGS2 (0.33) BPTFHPGDNPSR1RAB9AKDM4E
SCHEMBL4865901 0.65 KCNH2 (0.49) JAK2MAPK1
SCHEMBL3388145 0.65 ALDH1A1 (0.45) HPGDRAB9AKDM4EHTTHSD17B10
SCHEMBL4862922 0.65 KCNH2 (0.39) KMT2AJAK2SMN1; SMN2
SCHEMBL379746 0.62 KDR (0.39) RAB9AALDH1A1NPC1KMT2ALMNA
SCHEMBL2368309 0.61 LMNA (0.55) HPGDKDM4ETP53HTTHSD17B10
Ammonia Solution, Strong SCHEMBL1907515 0.61 L3MBTL1 (0.39) HPGDNPSR1RAB9AKDM4EHTT
SCHEMBL14342240 0.60 ALDH1A1 (0.42) HPGDNPSR1RAB9ATP53HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7456187-B2 Furanopyrimidine compounds as potassium ion channel inhibitors XENTION LIMITED (GB) 2008-11-25 US disclosed
EP-1758909-A1 FURANOPYRIMIDINE COMPOUNDS EFFECTIVE AS POTASSIUM CHANNEL INHIBITORS Xention Limited (GB) 2007-03-07 EP disclosed
WO-2005121149-A1 FURANOPYRIMIDINE COMPOUNDS EFFECTIVE AS POTASSIUM CHANNEL INHIBITORS XENTION DISCOVERY LIMITED (GB) 2005-12-22 WO disclosed
US-20050282829-A1 Furanopyrimidine compounds as potassium ion channel inhibitors XENTION DISCOVERY LTD. (GB) 2005-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282829-A1 Furanopyrimidine compounds as potassium ion channel inhibitors KCNH3, HCN4, KCNH2 BPTF 2197/4885HPGD 2400/4885NPSR1 100/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.